Extensive vascular remodeling in the spinal cord of pre-symptomatic experimental autoimmune encephalomyelitis mice; increased vessel expression of fibronectin and the α5β1 integrin

Amin Boroujerdi, Jennifer V. Welser-Alves, Richard Milner *

Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA

A R T I C L E   I N F O

Article history:
Received 22 February 2013
Revised 20 August 2013
Accepted 10 September 2013
Available online 20 September 2013

Keywords:
Experimental autoimmune encephalomyelitis (EAE) Vascular remodeling Angiogenesis Blood–brain barrier (BBB) Endothelial cells α5 integrin Fibronectin

A B S T R A C T

Alterations in vascular structure and function are a central component of demyelinating disease. In addition to blood–brain barrier (BBB) breakdown, which occurs early in the course of disease, recent studies have described angiogenic remodeling, both in multiple sclerosis tissue and in the mouse demyelinating model, experimental autoimmune encephalomyelitis (EAE). As the precise timing of vascular remodeling in demyelinating disease has yet to be fully defined, the purpose of the current study was to define the time-course of these events in the MOG35–51 EAE model. Quantification of endothelial cell proliferation and vessel density revealed that a large part of angiogenic remodeling in cervical spinal cord white matter occurs during the pre-symptomatic phase of EAE. At the height of vascular remodeling, blood vessels in the cervical spinal cord showed strong transient upregulation of fibronectin and the α5β1 integrin. In vitro experiments revealed that α5 integrin inhibition reduced brain endothelial cell proliferation under inflammatory conditions. Interestingly, loss of vascular integrity was evident in all vessels during the first 4–7 days post-immunization, but after 14 days, was localized predominantly to venules. Taken together, our data demonstrate that extensive vascular remodeling occurs during the pre-symptomatic phase of EAE and point to a potential role for the fibronectin–α5β1 integrin interaction in promoting vascular remodeling during demyelinating disease.

© 2013 Elsevier Inc. All rights reserved.

Introduction

Multiple sclerosis (MS) is a chronic inflammatory disease resulting in demyelination and degeneration of axons in the central nervous system (CNS). This results in disrupted nerve conduction, leading to physical and cognitive disabilities (ffrench-Constant, 1994; Lassmann, 1998). While the precise trigger of MS remains elusive, it is characterized pathologically by multiple inflammatory lesions of white matter that are separated in time and space. Though most of the damage is caused by infiltrating leukocytes, evidence suggests that alterations in blood vessel properties play a central role in the initiation and/or maintenance of this pathology (Roscoe et al., 2009; Seabrook et al., 2010). Blood–brain barrier (BBB) breakdown occurs at an early stage of MS (Gay and Esiri, 1991; Kirk et al., 2003), and is thought to be mediated in part by the action of proteases such as matrix metalloproteinase-9 (MMP-9) (Benveniste, 1997). These proteases degrade vascular basement membrane extracellular matrix (ECM) proteins such as laminins, collagen IV and fibronectin, as well as inter-endothelial tight junction proteins including claudin-5, ZO-1, and occludin (Rosenberg, 2002; Yong et al., 2001). BBB breakdown results in influx of inflammatory leukocytes and leakage of serum proteins such as fibrinogen, fibronectin and vitronectin, which together further amplify the inflammatory response via their activating influence on CNS-resident microglia (Adams et al., 2007; Milner et al., 2007).

Active angiogenic remodeling has been described both in MS (Holley et al., 2010; Ludwin et al., 2001) and in the animal model of MS, experimental autoimmune encephalomyelitis (EAE) (Kirk et al., 2004; Roscoe et al., 2009; Seabrook et al., 2010), resulting in increased vascular density. However, it is currently unknown whether these new vessels play a beneficial or harmful role in MS progression. One school of thought is that vascular remodeling is an integral part of the pathogenic process, whereby an abnormal vascular remodeling response leads to the formation of leaky angiogenic cerebral blood vessels (Holley et al., 2010; Roscoe et al., 2009; Seabrook et al., 2010). However, counter to this argument, recent studies have described hypoxic-like injury within MS lesions (Lassmann, 2003; Trapp and Stys, 2009), suggesting that hypoxia induces new vessel formation, which may be part of an endogenous protective response similar to that described in other neurodegenerative diseases, such as ischemic stroke (Greenberg and Jin, 2005; Wei et al., 2001) and Alzheimer’s disease (Wang et al., 2011). In animal models of ischemic stroke, hypoxic pre-conditioning promotes a strong angiogenic response (LaManna et al., 1992), and protects against ischemic infarct (Stowe et al., 2011). This raises the notion that angiogenic...
remodeling may be a general protective mechanism that acts to limit subsequent neurological insults. In support of this idea, cerebral vessels in hypoxic pre-conditioned mice showed elevated expression of tight junction proteins (Li et al., 2010a) and reduced leukocyte adherence post-stroke (Stowe et al., 2011), suggesting that angiogenic remodeling may promote tightening of the BBB and reduce leukocyte extravasation. More recently, Dore-Duffy and colleagues showed that chronic mild hypoxia reduced clinical severity of EAE and leukocyte infiltration into the CNS (Dore-Duffy et al., 2011).

It is a high priority to define the molecular mechanisms mediating vascular remodeling in EAE, as this could accelerate the design of clinical strategies aimed at manipulating vascular remodeling in MS. Vascular endothelial growth factor (VEGF) is elevated in MS (Proescholdt et al., 2002), and VEGF blockade inhibited angiogenesis and improved clinical score in EAE while attenuating demyelination and inflammation (Roscoe et al., 2009). Extracellular matrix (ECM) proteins also play a major role in vascular remodeling (Astrof and Hynes, 2009; Silva et al., 2008). This idea is supported by our recent finding that the fibronectin–α5β1 integrin interaction drives cerebral angiogenesis by promoting brain endothelial cell proliferation during cerebral hypoxia (Li et al., 2012b). Our current study had two goals. First, characterize the precise time-course of angiogenic remodeling at different stages of EAE, defining changes in vascular density, endothelial cell proliferation, and BBB integrity. Second, as angiogenic vessels in the hypoxic and ischemic CNS show strong upregulation of fibronectin and the α5β1 integrin (Li et al., 2012a; Milner et al., 2008a), determine whether this also occurs in EAE.

Materials and methods

Animals

The studies described have been reviewed and approved by The Scripps Research Institute Institutional Animal Care and Use Committee. Wild-type C57Bl/6 mice were maintained under pathogen-free conditions in the closed breeding colony of The Scripps Research Institute.

Experimental autoimmune encephalomyelitis (EAE)

EAE was performed using a protocol and materials provided by Hooke Laboratories (Lawrence, MA). Briefly, 8–10 week old C57Bl/6 female mice were immunized sub-cutaneously with 100 μl of 1 mg/ml MOG35–55 peptide emulsified in complete Freund’s adjuvant (CFA) containing 2 mg/ml Mycobacterium tuberculosis in both the base of the tail and upper back. In addition, on days 0 and 1, mice also received an intra-peritoneal injection of 275 ng pertussis toxin. Control mice received CFA and upper back. In addition, on days 0 and 1, mice also received an intra—limbs; 4

Immunohistochemistry and antibodies

Immunohistochemistry was performed as described previously (Milner and Campbell, 2002), on 10 μm frozen sections of cold PBS-perfused brain and cervical spinal cord. The following monoclonal antibodies were obtained from BD Pharmingen (La Jolla, CA): rat monoclonal antibodies reactive for CD31–FITC conjugated (clone MEC13.3), MHC class II (clone M5/114.15.2) and the α5 integrin subunit (clone 5H1027 (MFR5)). Other antibodies used included: rabbit anti-fibronectin, rabbit anti-laminins, and a mouse monoclonal anti-αβ-smooth muscle actin (SMA)-Cy3 conjugate (clone 1A4) (from Sigma, St. Louis, MO), rabbit anti-fibrinogen (Calbiochem, Billerica, MA), rabbit anti-iKb spindle/Cy3 (Vector Laboratories, Burlingame, CA), rat anti-MBP (Chemicon, Temecula, CA), and hamster anti-CD31 (clone 2H8; Abcam, Cambridge, MA). Secondary antibodies used included goat anti-Armenian hamster- DayLight 594 (Biolegend, San Diego, CA), anti-rat Alexa Fluor 488 (Invitrogen, Carlsbad, CA) and anti-rabbit and anti-rat Cy3 (Jackson Immunoresearch, Baltimore, PA).

Image analysis

Images were taken using a 20× objective on a Zeiss Imager M1.m (Thornwood, NY). Analysis was performed in the cervical spinal cord region. Three images were taken per region and the mean value calculated for each subject. All data analysis was performed using Perkin Elmer Volocity software (Waltham, MA). This includes quantification counts of α5 integrin and Ki67, sum area of CD31-positive vessels, and relative intensity of vascular fibronecin at different time points of EAE. Each experiment was performed with three different animals per condition, and the results expressed as the mean ± SEM. Statistical significance was assessed by using the Student’s t test, in which p < 0.05 was defined as statistically significant.

Brain endothelial cell culture

Pure cultures of mouse brain endothelial cells (BEC) were obtained as described previously (Milner et al., 2008b), with the modification that puromycin (4 μg/ml, Alexis GmbH, Grunberg, Germany) was included in culture media between days 1 and 3 to remove contaminating cell types. Endothelial cell purity was >95% as determined by CD31 in flow cytometry. BEC were used only for the first passage.

Proliferation assays

Glass coverslips were coated with fibronectin (Sigma, 10 μg/ml) for 2 h, then washed, and BEC plated and cultured until cells reached ~50% confluence. TNF-α was added (10 ng/ml, Genentech, San Francisco, CA) in the presence or absence of 5 μg/ml anti-α5 integrin function-blocking antibody (clone HMα5-1, BD Pharmingen) or isotype control, and BEC were cultured overnight in the presence of BrdU (Invitrogen, Carlsbad, CA), then fixed in acid/alcohol and processed for BrdU immunochemistry according to the manufacturer’s instructions. BEC proliferation was assessed by quantifying the number of BrdU-positive cells as a percentage of the total number of cells ( Hoechst staining), and the results expressed as the mean ± SEM of four experiments. Statistical significance was assessed by using Student’s t test, in which p < 0.05 was defined as statistically significant.

Results

Extensive vascular remodeling occurs in the spinal cord of pre-symptomatic EAE mice

EAE was induced in C57Bl/6 mice following immunization with MOG35–55 Peptide. In keeping with the findings from this lab and others, mice began developing symptoms 14 days post-immunization, clinical severity peaked around 21 days (acute symptomatic phase), and improved slightly thereafter, but never completely recovered at the experimental endpoint of 35 days (chronic symptomatic phase) (Fig. 1A) (Crocker et al., 2006; Maier et al., 2002; Milner et al., 2007). To examine the vascular changes that occur in the spinal cord at the different stages of EAE, we performed immunofluorescent (IF) staining with the endothelial cell marker CD31 on frozen sections of mouse cervical spinal cord, at 0, 4, 7, 14, 21 and 35 days post-immunization. By quantifying the total area of CD31+ vessels, this showed that total vascular area in the cervical spinal cord increased as early as 4 days post-immunization, and by 7 days was significantly elevated (126.0 ± 4.0% of the value of control mice, p < 0.01). This trend continued and
appeared to plateau between 21 and 35 days, with the total vascular area at 35 days increased to 153.4 ± 18.4% of the control value (p < 0.05) (Figs. 1B–C). Over the same time period, changes in vascular area were not observed in CFA control mice. This demonstrates that EAE is associated with a pronounced angiogenic remodeling response in the cervical spinal cord, culminating in increased numbers of blood vessels and a greater vessel area. Interestingly, a considerable part of this vascular remodeling occurs during the pre-symptomatic phase of EAE.

Cerebrovascular remodeling is associated with endothelial cell proliferation

To determine if the increased vascular area is the result of an active angiogenic response we performed dual-IF staining with the endothelial cell marker, CD31 and the cell proliferation marker Ki67. This revealed the presence of proliferating CD31-positive endothelial cells in remodeling vessels in the cervical spinal cord of EAE mice, but an absence of CD31/Ki67 dual-positive cells in control mice (0 day) (Figs. 2A–B). Quantification revealed that the number of CD31/Ki67 dual-positive cells increased during the development of EAE, reached a peak 14 days post-EAE induction (6.3 ± 0.7 CD31/Ki67 dual-positive cells/field compared to 0 in control mice, p < 0.001), and then diminished during the acute and chronic phases (Fig. 2C). These findings demonstrate an active angiogenic response in the EAE spinal cord, and reveal that the major angiogenic/endothelial proliferative response in EAE occurs prior to the development of symptoms. This results in an increased and sustained blood vessel density during the acute and chronic phases of EAE. To determine whether endothelial proliferation occurs in white or gray matter, we analyzed two adjacent sections, and stained one for myelin basic protein (MBP), and the other for CD31/Ki67. As shown in Figs. 3A–B, this revealed that CD31/Ki67 dual-positive proliferating endothelial cells were found predominantly in MBP-positive white matter (quantified in Fig. 3E).

BBB integrity is lost early in EAE

As BBB breakdown is an early event in MS (Gay and Esiri, 1991; Kirk et al., 2003), we next examined the time-course of vascular leakage in EAE by performing dual-IF for CD31 and fibrinogen. As shown in Figs. 4A and D, fibrinogen staining in CFA control mice (0 day) showed a perfectly overlapping pattern with the endothelial marker CD31, indicating that all fibrinogen was intravascular. However, as early as 4 and 7 days post-immunization, a disconnect appeared between CD31 and fibrinogen staining in EAE mice, in that fibrinogen staining extended beyond that of CD31, demonstrating loss of BBB integrity. Interestingly, in the spinal cord of 4 and 7 day post-immunized mice, fibrinogen leak was evident in all size vessels, but with increasing time (14 days onwards), the fibrinogen leak became more restricted to larger vessels. This is well illustrated in Fig. 4, which shows that at the 14 day,
21 day (acute), and 35 day (chronic) time-points, many large vessels showed fibrinogen leakage, indicating BBB breakdown, but the integrity of smaller vessels remained intact. Dual-IF with fibrinogen and another vascular marker, laminin, which demarcates the glia limitans, confirmed these findings (Fig. 4B). To determine which vessels leak in the acute and chronic symptomatic phases of EAE, we next performed dual-IF with fibrinogen and alpha-smooth muscle actin ($\alpha$-SMA), as $\alpha$-SMA is expressed at high levels in arterioles, and but is barely detectable in venules (Fig. 5A). This analysis revealed that both in the acute and chronic symptomatic stages of EAE (21 and 35 days respectively), diffuse extravascular fibrinogen staining was more strongly associated with venules (arrowheads) than arterioles (arrows) (Fig. 5B and quantified in Fig. 5C). Furthermore, dual-IF with laminin and MHC class II, a marker of infiltrating leukocytes, showed that in chronic EAE (day 35), infiltrating leukocytes were closely associated with post-capillary venules (Fig. 6). Interestingly, leukocyte accumulation in these vessels was associated with marked reduction in laminin staining of vessel walls (see arrow and arrowhead), consistent with the notion that leukocytes secrete MMPs to degrade vascular basement membrane proteins as part of the extravasation process (Gidday et al., 2005; Kelly et al., 2006).

Blood vessels in the spinal cord of pre-symptomatic EAE mice show increased expression of fibronectin and the $\alpha$5$\beta$1 integrin

In previous studies, we showed that angiogenic vessels in the hypoxic and ischemic CNS strongly upregulate expression of fibronectin and its receptor $\alpha$5$\beta$1 integrin (Li et al., 2010b; Milner et al., 2008a). Now, we addressed whether this holds true for remodeling vessels in the spinal cord of EAE mice. Consistent with previous findings, vessels in the normal CNS (CFA controls; 0 day) expressed low levels of fibronectin (Fig. 7A). By contrast, as early as 4 days post-immunization, vessels in the spinal cord of pre-symptomatic mice showed markedly elevated levels of fibronectin expression. Quantification of fluorescent intensity revealed that vascular fibronectin expression levels increased to reach a peak level 14 day post-immunization (146.7 ± 8.8% of control value, $p < 0.05$), and gradually decreased thereafter, such that fibronectin levels in the chronic phase were similar to CFA controls (quantified in Fig. 7B). In a parallel manner, while endothelial cells in the CFA control spinal cord expressed only low levels of $\alpha$5 integrin, this fibronectin receptor was strongly upregulated on vessels in the pre-symptomatic spinal cord, with the number of $\alpha$5 integrin-positive vessels per field increasing after 4, 7 and 14 days EAE, to 184 ± 5.8% ($p < 0.005$), 228 ± 51.8% ($p < 0.01$), and 260 ± 47.3% ($p < 0.005$) of the control value, respectively. In a similar manner to the temporal expression pattern of fibronectin, the number of $\alpha$5 integrin-positive vessels in the chronic phase of EAE had largely returned to CFA control levels (quantified in Fig. 7C). This demonstrates that remodeling blood vessels in the spinal cord transiently upregulate fibronectin and the $\alpha$5$\beta$1 integrin during the pre-symptomatic phase of EAE.

$\alpha$5 integrin blockade inhibits TNF-α-driven brain endothelial cell proliferation

Our previous studies described increased endothelial expression of $\alpha$5 integrin on cerebral vessels, both in mild hypoxia and following...
cerebral ischemia (Li et al., 2012a; Milner et al., 2008a). Functional analysis of a transgenic mouse lacking endothelial α5 integrin expression (α5-EC-KO mouse) revealed delayed and attenuated endothelial proliferation following mild hypoxia, suggesting an important proangiogenic role for endothelial α5β1 integrin (Li et al., 2012b). In light of our current findings, showing similar upregulation of endothelial α5 integrin on remodeling cerebral blood vessels during the early stages of EAE, we next examined in vitro whether α5 integrin mediates the BEC proliferative response to a pro-inflammatory stimulus. Previously, we found that TNF-α strongly stimulates BEC proliferation (Welser et al., 2010), and our current experiments, using bromodeoxyuridine (BrdU) incorporation, confirmed this finding, with TNF-α increasing proliferation (from 20.7 ± 1.8% under control conditions to 43.3 ± 2.9%, p < 0.001; see Fig. 7D). Furthermore, incubation with an α5 integrin function-blocking antibody significantly reduced brain endothelial cell proliferation under non-stimulated conditions (from 20.7 ± 1.8% to 16.3 ± 2.1%, p < 0.05) and in response to TNF-α (from 43.3 ± 2.9% to 22.5 ± 4.6%, p < 0.005). This demonstrates that α5 integrin mediates endothelial cell proliferation, suggesting that this is an important mechanism supporting angiogenic remodeling in EAE tissue.

Discussion

Alterations in vascular structure and function are a central component of demyelinating disease (Gay and Esiri, 1991; Kirk et al., 2003; Zlokovic, 2008). MRI studies in MS patients and studies of animal models demonstrate that BBB breakdown occurs early in the course of disease (Gay and Esiri, 1991; Kirk et al., 2003). More recently, angiogenic remodeling and increased vascular density have been described in MS (Holley et al., 2010; Ludwin et al., 2001) and EAE (Kirk et al., 2004; Roscoe et al., 2009; Seabrook et al., 2010). However, to date, the precise timing of the vascular remodeling events in demyelinating disease has not been fully defined. In the current study we examined these events in the MOG35–55 mouse model of EAE. Our main findings were: (i) extensive angiogenic remodeling in the cervical spinal cord occurs during the pre-symptomatic phase of EAE, with brain endothelial cell proliferation peaking at 14 days, resulting in increased blood vessel density at later time-points, (ii) vascular remodeling changes occurred predominantly in the myelinated regions, (iii) angiogenic blood vessels showed increased expression of fibronectin and the α5β1 integrin, (iv) inhibition of the α5 integrin reduced brain endothelial cell proliferation in a pro-inflammatory environment (TNF-α) in vitro, and (v) loss of vascular integrity was evident in all vessels during the first 4–7 days post-immunization, but after 14 days was localized specifically to venules. Taken together, our studies demonstrate that vascular remodeling occurs early in the development of EAE, and point to a potential role for the fibronectin–α5β1 interaction in driving this process.

The timing of vascular changes in demyelinating disease

Alterations in blood vessel form and function have been documented for over 140 years. In his histological studies, Rindfleisch observed that MS lesions were commonly associated with abnormal-looking
blood vessels (Rindfleisch, 1872). More recently, within the last ten years, MRI studies have described enhanced cerebral blood flow within relapsing-remitting and secondary-progressive MS lesions (Rashid et al., 2004), and one of these studies documented increased blood flow three weeks prior to gadolinium enhancement of the vessels, suggesting a potential role for vascular changes early in lesion evolution (Wuerfel et al., 2004). At the histological level, Ludwin described an increased number and size of vessels within acute MS lesions, as well as evidence of endothelial proliferation at this stage (Ludwin et al., 2001). A recent study confirmed these findings, showing increased vessel density at all stages of the MS lesion, and the highest levels of endothelial cell proliferation in normal appearing white matter in MS-affected brains (Holley et al., 2010). Consistent with these findings, our results show that extensive vascular remodeling occurs in

Fig. 4. Time-course of blood–brain barrier (BBB) disruption during EAE development. A. Dual IF for CD31 (Alexa Fluor-488, green) and fibrinogen (Cy3, red) was performed on frozen sections of cervical spinal cord taken from 0, 4, 7, 14, 21, and 35 days post-immunization. B. Dual IF for laminin (Alexa Fluor-488, green) and fibrinogen (Cy3, red). C. Dual IF for CD31 (Alexa Fluor-488, green) and MHC II (Cy3, red). D. Higher power (magnified) images taken from panels A and B. Scale bar (in A–C) = 100 μm. D. Scale bar = 50 μm. Note that no extravascular fibrinogen was evident in control tissue, and that while in 4 and 7 day EAE spinal cord, fibrinogen leak was evident in all size vessels, with increasing time (14 days onwards), fibrinogen leak was largely restricted to bigger vessels (see arrows). In contrast to fibrinogen leakage, leukocyte infiltration was not evident until day 14 post-immunization (see arrows in C). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
myelinated regions during the pre-symptomatic phase of EAE, and thus precede development of the MS lesion. However, a recent study in an alternative relapsing–remitting EAE model in the rat, challenged this consensus view by showing that the predominant vascular remodeling response in this particular model occurs during the relapsing phase of disease (Seabrook et al., 2010). This reinforces the need for caution when interpreting data from studies using different species and/or different animal models.

**Is angiogenic remodeling in demyelinating disease a good or a bad thing?**

Despite overwhelming evidence that vascular remodeling is an integral part of demyelinating disease in MS (Holley et al., 2010; Ludwin et al., 2001), and EAE (Kirk et al., 2004; Roscoe et al., 2009; Seabrook et al., 2010), it has yet to be determined whether this is harmful or beneficial to the patient. The current consensus leans strongly towards the idea that vascular remodeling in demyelinating disease is destructive and part of the pathogenesis of demyelinating lesions (Holley et al., 2010; Kirk et al., 2004; Roscoe et al., 2009). Early in the evolution of lesions, a hypoxic-like state exists as a result of loss of efficient salutary conduction leading to increased energy demand (Lassmann, 2003; Trapp and Stys, 2009), which in turn leads to release of angiogenic growth factors, such as VEGF (Roscoe et al., 2009). Significantly, VEGF blockade inhibited angiogenesis and improved clinical score in EAE while attenuating demyelination and inflammation (Roscoe et al., 2009), thus providing the first evidence that vascular remodeling contributes to demyelinating pathogenesis, and that blockade of angiogenic factors could be beneficial in the treatment of MS. Our finding, that vascular remodeling precedes the development of acute demyelinated lesions is certainly consistent with a pathogenic role for vascular remodeling. However, evidence from other neurological diseases suggests that a state of hypoxic-induced angiogenic remodeling might actually be beneficial. For instance, in mice models of ischemic stroke, hypoxic pre-conditioning promotes a strong angiogenic response, which results in smaller ischemic infarcts (Miller et al., 2001; Stowe et al., 2011). Taken with the finding that VEGF-induced angiogenesis ameliorates cognitive decline in a mouse model of Alzheimer’s disease (Wang et al., 2011), this suggests that at least in these conditions, angiogenic remodeling protects against subsequent neurological insult. Interestingly, recent experiments in the EAE model showed that hypoxic pre-conditioning reduced clinical severity of EAE as well as reducing leukocyte infiltration (Dore-Duffy et al., 2011). Thus, while the timing of vascular remodeling, early in demyelinating disease, is consistent with a causative role in disease pathogenesis, at the current time, it cannot be excluded that certain aspects of this remodeling might be protective. It is most likely that vascular remodeling during demyelinating disease encompasses both harmful (e.g.: BBB breakdown) and beneficial (e.g.: formation of new blood vessels) components. We have shown in the chronic hypoxia model of cerebrovascualar remodeling, that angiogenesis proceeds in the absence of BBB breakdown, resulting in increased tight junction protein expression (Li et al., 2010a). This demonstrates that angiogenesis is not inextricably linked to BBB breakdown. Most likely the outcome of vascular remodeling depends on the overall balance of vessel-modulatory factors, and that in comparison to the mild hypoxic situation, the acutely demyelinating region contains an excess of pro-inflammatory mediators and angiogenic factors that results in the production of incompletely assembled, leaky vessels. If this proves to be correct, then perhaps future therapeutic efforts should be based less on total blockade of vascular remodeling, and more on targeting the response to produce functional new vessels with high vascular integrity.

**Upregulation of fibronectin and the α5β1 integrin on angiogenic vessels in EAE spinal cord**

One of the main goals of this study was to determine whether remodeling vessels in the EAE spinal cord showed altered expression of fibronectin and the α5β1 integrin, and indeed we found this to be true. These findings are consistent with our recent work describing elevated expression levels of fibronectin and the α5β1 integrin on angiogenic vessels under conditions of cerebral hypoxia or ischemia (Li et al., 2012a; Milner et al., 2008a), though interestingly, the time-course of expression varies somewhat between the different models. In the chronic mild hypoxia model, levels of fibronectin and the α5β1 integrin peak after 4 days hypoxia and then decline (Li et al., 2010a), while in the EAE model, these levels are extended over a longer time course, peaking after 14 days, before declining. Interestingly, in both models there is a tight correlation between the peak of fibronectin/α5β1 integrin expression, and the maximum rate of endothelial proliferation. This

---

**Fig. 5.** Fibrinogen leakage in the acute and chronic stages of EAE is largely restricted to venules. A. Dual IF for CD31 (Alexa Fluor-488, green) and α-SMA (Cy3, red) was performed on frozen sections of cervical spinal cord. Scale bar = 100 μm. Note that α-SMA strongly labels arterioles (labeled A) but is barely detectable in venules (labeled V). B. Dual IF for fibrinogen (Alexa Fluor-488, green) and α-SMA (Cy3, red) was performed on frozen sections of cervical spinal cord taken from 21 (acute) and 35 day (chronic) EAE tissue. Scale bar = 100 μm. Note that in the acute and chronic stages of EAE, diffuse extravascular fibrinogen leakage was predominantly associated with venules (arrowheads), rather than arterioles (arrows). C. Quantification of fibrinogen leakage from arterioles and venules at different stages of EAE development. Data points represent the mean ± SEM of 3 experiments. Note that fibrinogen leakage occurs predominantly from venules, particularly in chronic EAE (35 day time-point). *p < 0.05, **p < 0.01. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
demonstrates that in EAE, a large part of the angiogenic remodeling occurs prior to the onset of neurological symptoms.

Fibronectin is a major inducer of angiogenic remodeling in many systems, both during development, and in physiological and pathological remodeling in the adult (Astrof and Hynes, 2009; Kim et al., 2000; Risau and Lemmon, 1988; Tonnensen et al., 1985). Recently we demonstrated the importance of the fibronectin–α5β1 axis in cerebral vascular remodeling by showing that mutant mice lacking endothelial α5 integrin, showed a delayed and attenuated angiogenic response to cerebral hypoxia (Li et al., 2012b). Based on this finding, we suggested that manipulation of the fibronectin–α5β1 axis might provide a therapeutic approach to enhance cerebral angiogenesis in the ischemic CNS, and by inference, a similar approach could be used to regulate vascular remodeling in demyelinating disease. However, as it is currently unclear whether angiogenic remodeling has beneficial or deleterious effects in demyelinating disease, it is impossible to predict if such a strategy would involve stimulation or inhibition of α5 integrin-mediated angiogenesis. In light of the urgency of this question, we plan to address this critical gap in knowledge by examining vascular changes and EAE progression in mice lacking endothelial α5 integrin expression.
(α5-EC-KO transgenic mice), which show a markedly attenuated angiogenic response to cerebral hypoxia (Li et al., 2012b). Using this approach, we should be able to shed light on two key questions: (i) is α5 integrin required for mediating angiogenic changes in EAE, and if, as predicted, this turns out to be correct, (ii) use α5-EC-KO mice to delay the angiogenic process, in order to answer the question: what effect does blocking angiogenesis have on clinical progression in EAE?

Acknowledgments

This work was supported by a Postdoctoral Fellowship Award from the American Heart Association (AB) and by the NIH RO1 grant NS060770 (RM). This is manuscript number 23902 from The Scripps Research Institute.

References


